BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37688511)

  • 1. Transthyretin promotes the invasion of combined hepatocellular cholangiocarcinoma by tumor-associated macrophages.
    Ke K; Lin J; Huang N; Yan L; Liao R; Yang W
    Cancer Rep (Hoboken); 2023 Oct; 6(10):e1888. PubMed ID: 37688511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
    Wang C; Chen C; Hu W; Tao L; Chen J
    Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
    Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
    Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD147 augmented monocarboxylate transporter-1/4 expression through modulation of the Akt-FoxO3-NF-κB pathway promotes cholangiocarcinoma migration and invasion.
    Dana P; Saisomboon S; Kariya R; Okada S; Obchoei S; Sawanyawisuth K; Wongkham C; Pairojkul C; Wongkham S; Vaeteewoottacharn K
    Cell Oncol (Dordr); 2020 Apr; 43(2):211-222. PubMed ID: 31729681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
    Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
    Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice.
    Liu Y; Xin B; Yamamoto M; Goto M; Ooshio T; Kamikokura Y; Tanaka H; Meng L; Okada Y; Mizukami Y; Nishikawa Y
    Cancer Sci; 2021 Aug; 112(8):3111-3124. PubMed ID: 34051011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M2-polarized tumor-associated macrophages promote epithelial-mesenchymal transition via activation of the AKT3/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma.
    Sun D; Luo T; Dong P; Zhang N; Chen J; Zhang S; Dong L; Janssen HLA; Zhang S
    J Cell Biochem; 2020 Apr; 121(4):2828-2838. PubMed ID: 31692069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma.
    Murugesan K; Sharaf R; Montesion M; Moore JA; Pao J; Pavlick DC; Frampton GM; Upadhyay VA; Alexander BM; Miller VA; Javle MM; Bekaii Saab TS; Albacker LA; Ross JS; Ali SM
    JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARHGAP21 Is Involved in the Carcinogenic Mechanism of Cholangiocarcinoma: A Study Based on Bioinformatic Analyses and Experimental Validation.
    Wang Z; Wu S; Wang G; Yang Z; Zhang Y; Zhu C; Qin X
    Medicina (Kaunas); 2023 Jan; 59(1):. PubMed ID: 36676763
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling.
    Rosenberg N; Van Haele M; Lanton T; Brashi N; Bromberg Z; Adler H; Giladi H; Peled A; Goldenberg DS; Axelrod JH; Simerzin A; Chai C; Paldor M; Markezana A; Yaish D; Shemulian Z; Gross D; Barnoy S; Gefen M; Amran O; Claerhout S; Fernández-Vaquero M; García-Beccaria M; Heide D; Shoshkes-Carmel M; Schmidt Arras D; Elgavish S; Nevo Y; Benyamini H; Tirnitz-Parker JEE; Sanchez A; Herrera B; Safadi R; Kaestner KH; Rose-John S; Roskams T; Heikenwalder M; Galun E
    J Hepatol; 2022 Dec; 77(6):1631-1641. PubMed ID: 35988690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
    Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
    Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic activity of retinoic acid receptor γ is exhibited through activation of the Akt/NF-κB and Wnt/β-catenin pathways in cholangiocarcinoma.
    Huang GL; Luo Q; Rui G; Zhang W; Zhang QY; Chen QX; Shen DY
    Mol Cell Biol; 2013 Sep; 33(17):3416-25. PubMed ID: 23798555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
    Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
    Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Annexin A1: A new immunohistological marker of cholangiocarcinoma.
    Hongsrichan N; Rucksaken R; Chamgramol Y; Pinlaor P; Techasen A; Yongvanit P; Khuntikeo N; Pairojkul C; Pinlaor S
    World J Gastroenterol; 2013 Apr; 19(16):2456-65. PubMed ID: 23674846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGFBP7 is associated to prognosis and could suppress cell survival in cholangiocarcinoma.
    Yue C; Yang M; Tian Q; Mo F; Peng J; Ma Y; Huang Y; Wang D; Wang Y; Hu Z
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):817-825. PubMed ID: 29991293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
    Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
    Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homophilic Interaction of CD147 Promotes IL-6-Mediated Cholangiocarcinoma Invasion via the NF-κB-Dependent Pathway.
    Dana P; Kariya R; Lert-Itthiporn W; Seubwai W; Saisomboon S; Wongkham C; Okada S; Wongkham S; Vaeteewoottacharn K
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.